Virus Filtration Market
Number of pages: 100 | Report Format: PDF | Published date: April 19, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 4.29 Billion |
|
Market Size Value in 2031 |
US$ 10.11 Billion |
|
CAGR |
10% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Product, Technology, Application, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global Virus Filtration Market was valued at US$ 4.29 billion in 2022 and is expected to register a revenue CAGR of 10% to reach US$ 10.11 billion by 2031.
Virus Filtration Market Fundamentals
Viral filtration uses a membrane barrier to keep virus particles in place, providing a crucial defense against unexpected viruses. The safety of biopharmaceutical medicinal products will greatly depend on pharmaceutical companies’ increased spending on virus filtration. Market players anticipate that North America and Europe will remain the two largest markets as they invest in cutting-edge technologies.
Virus filtration and ultrafiltration are two significant technologies in biopharmaceutical manufacturing, often used in the final two phases of downstream antibody processing. Removing potentially dangerous viral contamination from biopharmaceutical pharmaceuticals has long been a problem, both for early plasma-derived drug products and contemporary animal cell culture-derived drug products. Virus safety has changed over time in the biopharmaceutical business. Virus filtration has played and continues to play an important part in the process safety objective for biopharmaceutical medicinal products.
The presence of viruses in the final result is one component that poses a risk to the patient. The presence of viruses in products produced from human or animal cells might have devastating clinical effects. As a result, regulatory agencies emphasize the importance of implementing robust and orthogonal viral clearance procedures to fulfill the requirements of a risk-based approach to virus clearance evaluation.
Virus filtering has long been recognized as a reliable method of virus removal. For instance, the Virosart HF viral filter series combines a high flow rate, high virus retention, and increased product throughput with efficient and robust virus clearance technology for tiny, non-enveloped, and large enveloped viruses.
[11]
Virus Filtration Market Dynamic
The adoption of single-use technologies, increased viral contamination of treatments, rising R&D spending, and government backing are factors propelling the global virus filtration revenue. Outsourcing in the pharmaceutical industry and developing nations is a sign of potential market revenue growth. The demand for biologics is expected to increase due to the rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders.
The need for virus elimination while manufacturing monoclonal antibodies (MAbs) has boosted the possibilities in the virus filtration industry. Over the last few years, amazing technological breakthroughs in mAb downstream processes have been accomplished, with new mAb platforms looking promising. The increased need for high-concentration monoclonal antibody solutions in the health sciences sectors has prompted viral filtration manufacturers to focus on various performance factors. Major characteristics, for example, are connected to quick clearing, high flow, and high capacity. New viral filter screening setups have evolved. Most significantly, end users in the health sciences industry seek viral filtration technologies allowing cost-effective filtering. The idea has gained traction recently due to increased demand for environmentally friendly mAb production procedures. The increasing use of plasma processing in clinical research has increased the demand for continual technical advancements in the virus-filtering industry. The growing number of investigational new medication filings is also helping to broaden the path. In addition, the increasing utilization of mammalian cell lines in manufacturing mAbs is driving the market revenue share.
The continual processing within the virus filter might not function as expected, resulting in unsuccessful batches of items and limiting market revenue expansion. Virus filtration is an important downstream operation; virus filtering can be done in batches or continuously. The batch systems in continuous viral filtration are closed and more complicated. Hence, the variable in protein content, irregularity of pH values, and conductivity challenge the virus filter. Furthermore, the filters are tested when the minimum titer is 106 pfu/ml. Moreover, enterprises must pay additional funds to perform parallel filtration, allowing in-line testing during the continuous phase of batch filtering.
Virus Filtration Market Ecosystem
The global virus filtration market is analyzed from four perspectives: product, technology application, and region.
Virus Filtration Market Product
Based on product, the global virus filtration market is segmented into consumables, instruments, and services. The consumables are further sub-segmented into kits, reagents, and others, whereas instruments are also sub-segmented into filtration and chromatography systems.
The consumable segment dominated the market during the forecast period because these products are used more often for viral filtration. Reagents, kits, and membranes will likely increase in demand as more attention is paid to developing vaccines, protein treatments, blood products, cellular therapy products, gene therapy products, tissue products, and stem cell products.
The instruments segment is expected to grow rapidly in terms of revenue share during the forecast period because of the rising demand for biological therapies to treat chronic illnesses. Biotechnology and biopharmaceutical companies such as F. Hoffmann-La Roche Ltd., Pfizer Inc., and Amgen Inc. invest in sophisticated filtration and chromatography equipment for biologics research and development.
The services segment is expected to exhibit the greatest revenue CAGR during the forecast period. The biotechnology industry is increasingly outsourcing R&D and drug development services to CROs. Furthermore, CROs are cooperating with biotechnology and biopharmaceutical businesses to create innovative drugs and therapies, projected to drive the segment’s revenue growth.
Virus Filtration Market Technology
[125]
Based on technology, the global virus filtration market has been segmented into filtration and chromatography.
The filtration segment dominated during the forecast period due to the increased use of these goods in research, medical device manufacturing, and biologics production. Additionally, it offers a number of benefits, including not denaturing the proteins in the product or sample and excellent efficacy and purity on both a small- and large-scale operation.
Virus Filtration Market Application
Based on application, the global virus filtration market is segmented into biologicals, stem cell products, medical devices, water purification, and air purification. The biologicals are sub-segmented into vaccine and therapeutics, blood and blood products, cellular and gene therapy products, and tissue & tissue products.
The biological segment dominated the market in terms of revenue share during the forecast period. This can be linked to the rising incidence of chronic diseases that increase demand for biologics, such as growth hormone deficiency, blood disorders, cancer, diabetes, and autoimmune disorders.
Virus Filtration Market End User
Based on end users, the global virus filtration market is segmented into biopharmaceuticals and biotechnology, contract research organization, medical devices company, and academic institutes and research laboratories.
The biopharmaceuticals and biotechnology segment dominated the market during the forecast period due to rising R&D efforts, biologics output, and expansion of the biopharmaceutical industry. Virus filtration technology is widely used in the United States, Germany, the United Kingdom, Japan, China, and India. Having large biopharmaceutical and biotechnology companies nearby, having a strong healthcare system, and having access to cutting-edge products are driving the segment’s revenue share.
The contract research organization segment is expected to increase the most during the forecast period because of the trend of outsourcing R&D and production to CROs. The number of vaccine and therapeutic protein production businesses has increased the demand for outsourcing services catering to these companies’ specialized demands.
During the forecast period, the medical device businesses segment is expected to register a considerable revenue CAGR. Viral elimination agents are commonly employed in medical devices such as anesthesia systems and ventilators. Humid-Vent HEPA, for example, is a mechanical viral and bacterial filter intended for use in bacterial/viral filtration and humidification in ventilator and anesthesia systems.
Virus Filtration Market Region
Based on region, the global virus filtration market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the global virus filtration market revenue share, which is expected to continue growing during the forecast period. The established biotechnology and biopharmaceutical sectors in the United States have increased the region’s demand for improved viral clearance products for research and development and biologics manufacturing. Due to the significant demand for novel virus filtration products for research and the development and manufacturing of biologics, Europe was the second-largest market. The regional revenue share is also expected to be driven by highly developed healthcare infrastructure and significant R&D investments, particularly in Germany, the United Kingdom, and France.
During the forecast period, Asia Pacific is expected to account for the highest revenue CAGR. According to estimates, the region’s revenue growth will be fuelled by the existence of untapped revenue growth prospects in the quickly expanding Asian economies of China, India, and Indonesia. Additionally, the growth in Asian nations such as India and Indonesia drives territorial development. Rising government support for industrialization, growing closeness of CROs, simplicity of labor, and considerably less strict administrative conditions are attracting producers of biologics and medical devices to expand in these geographies.
Competitive Landscape of the Global Viral Filtrations Market
The virus filtration market has a few competitors and is moderately competitive. Few of the top companies now control the industry under study in terms of market revenue share. Some other minor competitors are anticipated to enter the market under study during the forecast period due to the rising R&D of biopharmaceutical businesses and the high prevalence of disorders. Some of the prominent market players operating in the global viral filtrations market are:
Strategic Development in Global Viral Filtrations Market
Asia Pacific is the key growth region in the global virus filtration market.
The increasing development in pharma and biotechnology companies and rising research and development activities are the key driving factors for the global virus filtration market revenue.
The expected size of the virus filtration industry in 2031 is 10.11 billion.
The revenue CAGR of the virus filtration market during the forecast period will be 10%.
Some prominent players operating in the global viral filtrations market are Merck KGaA, Asahi Kasei Corporation, and BioProcess International.
*Insights on financial performance is subject to availability of information in public domain